Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-03-04FDA Approved: REMERON — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for REMERON (mirtazapine) filed by Organon LLC.
-
FDA approval · 2020-03-04FDA Approved: REMERONSOLTAB — Supplemental Application (Organon LLC)
The FDA lists a supplemental application for REMERONSOLTAB (mirtazapine) submitted by Organon LLC, indicating an ongoing regulatory action f…
-
CLINICAL_TRIALS trial_result · 2020-03-03Clinical Trial Update: Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics [Phase 2]
Phase 2 clinical trial evaluating incorporating patient treatment choice to improve treatment retention in depressed Hispanics with major de…
-
CLINICAL_TRIALS trial_result · 2020-02-27Clinical Trial Update: Loving-Kindness Meditation for PTSD [NA]
Clinical trial update indicating completion and posted results for loving-kindness meditation in PTSD and depression.
-
CLINICAL_TRIALS trial_result · 2020-02-26Clinical Trial Update: Impact of Duloxetine on Male Fertility [Phase 2]
A Phase 2 trial evaluating duloxetine for male infertility and depression has completed and posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-02-21FDA Approved: SERTRALINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for sertraline from Heritage Pharmaceuticals (d/b/a Avet), signaling approval of a change or additio…
-
FDA approval · 2020-02-21FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride (generic sertraline).
-
FDA approval · 2020-02-21FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for an additional generic version of sertraline hydrochloride, expanding the availability of this an…
-
FDA approval · 2020-02-20FDA Approved: ARIPIPRAZOLE — Supplemental Application (Dr.Reddys Laboratories Inc)
The FDA approved a supplemental application for aripiprazole from Dr. Reddy's Laboratories Inc., supporting regulatory action for the generi…
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects [Phase 4]
Phase 4 clinical trial evaluating the effects of an antidepressant vs placebo on brain functioning in adults with depression; completed with…
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy [Phase 2]
Phase 2 clinical trial assessing acupuncture and moxibustion effects on major depressive disorder with functional near-infrared spectroscopy…
-
CLINICAL_TRIALS withdrawal · 2020-02-11Clinical Trial Update: Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department [Phase 2, Phase 3]
A clinical trial investigating single-dose ketamine for acute pain and depression in the emergency department was withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: Treatment of Depression in Acute Coronary Syndrome (ACS) Patients [NA]
Clinical trial evaluating treatment of depression in patients with acute coronary syndrome has completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-10Clinical Trial Update: New Haven MOMS Partnership [NA]
A completed clinical trial conducted by Yale University examining depression and stress; results posted in 2020.
-
FDA approval · 2020-02-06FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals' supplemental abbreviated new drug application for aripiprazole, granting approval of a generic version.
-
FDA approval · 2020-02-05FDA Approved: ARIPIPRAZOLE — Supplemental Application (Lannett Company, Inc.)
The FDA approves a supplemental application for ARIPIPRAZOLE (Aripiprazole) from Lannett Company, expanding approval of a generic antipsycho…
-
FDA approval · 2020-02-05FDA Approved: ARIPIPRAZOLE — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.’s supplemental application for aripiprazole (generic aripiprazole), authorizing the sale of a generic version of t…
-
FDA approval · 2020-02-05FDA Approved: ARIPIPRAZOLE — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved Dr. Reddy's supplemental application to manufacture and market aripiprazole orally disintegrating tablets as a generic product.
-
FDA approval · 2020-02-05FDA Approved: TRAZODONE HYDROCHLORIDE — Original Application (Aurolife Pharma LLC)
The FDA approved an original application for trazodone hydrochloride tablets from Aurolife Pharma LLC, enabling generic access.
-
FDA label_change · 2020-02-05FDA Approved: SEROQUEL — Supplemental Application (H2-Pharma, LLC)
FDA approved a supplemental application for SEROQUEL (quetiapine) submitted by H2-Pharma, LLC, affecting the product labeling. The action re…
-
FDA approval · 2020-02-05FDA Approved: ARIPIPRAZOLE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approves a supplemental application for a generic version of aripiprazole from Alembic Pharmaceuticals Inc.
-
FDA approval · 2020-02-04FDA Approved: ARIPIPRAZOLE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' supplemental application to market a generic ARIPIPRAZOLE under an ANDA.
-
FDA approval · 2020-02-04FDA Approved: ARIPIPRAZOLE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ARIPIPRAZOLE from Aurobindo Pharma Limited, indicating regulatory clearance for changes to the a…
-
FDA approval · 2020-01-31FDA Approved: VIIBRYD — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for VIIBRYD (vilazodone hydrochloride) submitted by Allergan, Inc., updating the labeling to reflect…
-
CLINICAL_TRIALS withdrawal · 2020-01-28Clinical Trial Update: Endogenous Opioid Modulation by Ketamine [Phase 3]
Phase 3 clinical trial on endogenous opioid modulation by ketamine for major depressive disorder has been withdrawn.